Related Experiment Video
Updated: Feb 2, 2026

Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae
Published on: June 13, 2025
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter
Jason C Gallagher1, Michael J Satlin2, Abdulrahman Elabor3
1Temple University, Department of Pharmacy Practice, Philadelphia, Pennsylvania.
Background:
Multidrug-resistant Pseudomonas aeruginosa infections remain common in hospitals worldwide. We investigated the outcomes associated with the use of ceftolozane-tazobactam for the treatment of these infections.
Methods:
Data were collected retrospectively from 20 hospitals across the United States about adults who received ceftolozane-tazobactam for the treatment of multidrug-resistant P aeruginosa infections of any source for at least 24 hours. The primary outcome was a composite of 30-day and inpatient mortality, and secondary outcomes were clinical success and microbiological cure. Multivariable regression analysis was conducted to determine factors associated with outcomes.
Results:
Two-hundred five patients were included in the study. Severe illness and high degrees of comorbidity were common, with median Acute Physiology and Chronic Health Evaluation (APACHE) II scores of 19 (interquartile range [IQR], 11-24) and median Charlson Comorbidity Indexes of 4 (IQR, 3-6). Delayed initiation of ceftolozane-tazobactam was common with therapy started a median of 9 days after culture collection. Fifty-nine percent of patients had pneumonia. On susceptibility testing, 125 of 139 (89.9%) isolates were susceptible to ceftolozane-tazobactam. Mortality occurred in 39 patients (19%); clinical success and microbiological cure were 151 (73.7%) and 145 (70.7%), respectively. On multivariable regression analysis, starting ceftolozane-tazobactam within 4 days of culture collection was associated with survival (adjusted odds ratio [OR], 5.55; 95% confidence interval [CI], 2.14-14.40), clinical success (adjusted OR, 2.93; 95% CI, 1.40-6.10), and microbiological cure (adjusted OR, 2.59; 95% CI, 1.24-5.38).
Conclusions:
Ceftolozane-tazobactam appeared to be effective in the treatment of multidrug-resistant P aeruginosa infections, particularly when initiated early after the onset of infection.
Insights
Ceftolozane-tazobactam effectively treats multidrug-resistant Pseudomonas aeruginosa infections. Early initiation of this antibiotic within 4 days of culture collection significantly improves patient survival and treatment success.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Multidrug-resistant Pseudomonas aeruginosa (MDRP) infections pose a significant global healthcare challenge.
- Ceftolozane-tazobactam is an antibiotic option for treating MDRP infections.
Purpose of the Study:
- To evaluate the clinical outcomes of ceftolozane-tazobactam treatment for MDRP infections.
- To identify factors associated with treatment success in a real-world setting.
Main Methods:
- Retrospective data collection from 20 US hospitals.
- Inclusion of adult patients treated with ceftolozane-tazobactam for MDRP infections for at least 24 hours.
- Primary outcome: composite of 30-day and inpatient mortality; Secondary outcomes: clinical success and microbiological cure.
Main Results:
- 205 patients were analyzed, with severe illness and comorbidities being common.
- Ceftolozane-tazobactam susceptibility was high (89.9%).
- Early treatment initiation (within 4 days of culture) was significantly associated with improved survival (aOR 5.55), clinical success (aOR 2.93), and microbiological cure (aOR 2.59).
Conclusions:
- Ceftolozane-tazobactam demonstrates efficacy in treating MDRP infections.
- Timely administration of ceftolozane-tazobactam is crucial for optimizing patient outcomes.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...

